Wendy Smith Begolka, MBS, shares strategies to better meet the needs of patients with chronic inflammatory skin diseases.

One night, I was in the pub with a friend when a man came up to me. He looked a bit drunk as he pointed at the skin between my shoulder blades with a sneer. ‘You’ve got ringworm,’ he announced.

Johnson & Johnson (JNJ) stock is in focus as US approves its once-daily pill Icotyde developed with Protagonist Therapeutics (PTGX) for plaque psoriasis. Read more here.

The first-of-its-kind oral pill could replace injectable medications for some patients with psoriasis, dermatologists say.

By Sriparna Roy March 18 (Reuters) - The U.S. Food and Drug Administration has approved Johnson & Johnson's oral pill for ...

FDA approval covers adults and adolescents ≥12 years (≥88 lbs) with moderate-to-severe plaque psoriasis requiring systemic therapy or phototherapy, expanding systemic options beyond injectables.

The FDA has approved the first oral interleukin (IL)-23-targeted therapy for plaque psoriasis, Johnson & Johnson announced. The approval of icotrokinra (Icotyde) stipulates use in adults and children ...

Johnson & Johnson and Protagonist Therapeutics are countering the swarm of injectable biologics that have long dominated the lucrative psoriasis market with a new approval for a much-anticipate | The ...

SALT LAKE CITY, UT, UNITED STATES, March 16, 2026 /EINPresswire.com/ -- The National Psoriasis Foundation (NPF) will ...

Psoriasis is an autoimmune condition that causes rough patches of skin. The new once-daily Icotyde pill, is an interleukin-23 (IL-23) receptor antagonist that has been found safe and also delivers ...

Johnson & Johnson said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots.

The FDA approved icotrokinra for adults and adolescents aged 12 years and older with moderate to severe plaque psoriasis, Johnson & Johnson announced in a press release. Icotrokinra (Icotyde) is the ...